To control obesity and diabetes worldwide, many companies have developed GLP-1 and Semaglutide drugs that have controlled diabetes and have helped overweight people to lose weight. Monzaro and Vagovi have been officially launched in India, but now it is reported that the Central Drug Standards Control Organization (CDSCO) has approved Novo Nordisk’s blockbuster medicine, ozmpic (semaglutide injection) for use in India. This approval, which is valid until 26 September, 2025, allows the use of ozmpic with diet and exercise for type 2 diabetes.
What are Ozmpic, Monjaro and Vegovi?
Over the years, obesity and diabetes control drugs have surfaced, which are available in the form of injections and are given once a week. Currently, only Monjaro and Vegovi are available in India, and ozmpic, which has been approved, will also be available in the near future. The ozmpic and vegovi are produced by Novo Nordisk, while Monzaro is formed by Eli Lily. The main ingredient in ozmpic and vegovi is semaglutide, while Monzaro contains tirzepatide. Ozmpic and Monjaro were originally developed for the management of type 2 diabetes, but the vegovi has received the approval of FDA specifically for weight loss.
How do ozmpic, monjarso and vegovi work
Ozmpic, monsarro and vegovi mimic hormones controlling hunger and sugars in the body. Ozmpic and vegovi are GLP-1 receptor agonists, which help you keep the stomach emptied and keep you full for a long time. It reduces appetite and helps control blood sugar. On the other hand, Monzaro acts as a double GIP and GLP-1 receptor agonist, which not only reduces appetite but also increases fat burning and weight loss. Clinical trials have shown that ozmpic and vegovi can lose an average of 10–15% on an average, while Monjaro may lose about 20%.
Price of ozmpic, Monjaro and Vegovi in India
Ozmpic has just received approval for use in India, so the company has not yet confirmed the correct price of this drug. Monzaro is available in India in doses of 2.5 mg and 5 mg. The price of 2.5 mg of medicine is ₹ 3,500 and 5 mg vial is ₹ 4,375. This medicine is given once a week. The monthly cost of 2.5 mg (4 weeks) is ₹ 14,000, and the monthly cost of 5 mg is about ₹ 17,500. Wagovi has been launched in five doses in India: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg. The dose of 0.25 mg, 0.5 mg and 1 mg is priced ₹ 4,366. The dose of 1.7 mg is priced at ₹ 6,070 and the dose of 2.4 mg is ₹ 6,503.
Profit and losses
The biggest advantage of ozmpic, Monjaro and Vagovi is that they help control diabetes. These medicines can also help in weight loss. Some drugs have also shown positive effects on heart health and lifestyle diseases. The company claims that ozmpic may also be beneficial for heart and kidneys. However, ozmpic has not been approved to treat obesity. Along with its benefits, there are some disadvantages of these drugs, listed on their official websites. Common side effects include nausea, vomiting, constipation, abdominal pain and fatigue. Long -term use has also been linked to the risk of thyroid tumors (seen in animals), pancreatitis and gall bladder problems.
